List of Excipients in Branded Drug QINLOCK

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Deciphera Pharmaceuticals LLC	QINLOCK	ripretinib	73207-101	CELLULOSE, MICROCRYSTALLINE	2040-12-30
Deciphera Pharmaceuticals LLC	QINLOCK	ripretinib	73207-101	CROSPOVIDONE	2040-12-30
Deciphera Pharmaceuticals LLC	QINLOCK	ripretinib	73207-101	HYPROMELLOSE ACETATE SUCCINATE 06081224	2040-12-30
Deciphera Pharmaceuticals LLC	QINLOCK	ripretinib	73207-101	LACTOSE MONOHYDRATE	2040-12-30
Deciphera Pharmaceuticals LLC	QINLOCK	ripretinib	73207-101	MAGNESIUM STEARATE	2040-12-30
Deciphera Pharmaceuticals LLC	QINLOCK	ripretinib	73207-101	SILICON DIOXIDE	2040-12-30

Qinlock Excipient Strategy and Commercial Opportunities for Ripretinib

Last updated: August 23, 2026

Qinlock (ripretinib) is a 50 mg film-coated immediate-release tablet marketed by Deciphera Pharmaceuticals, now part of Ono Pharmaceutical. Its commercial formulation uses conventional solid-oral excipients, creating limited opportunity for direct substitution but meaningful openings in qualified excipient supply, coating systems, global manufacturing, lifecycle reformulation, and generic development. The strongest near-term commercial opportunity is reliable, regulatory-compliant supply of pharmaceutical-grade excipients for chronic oncology treatment, not a novel excipient platform.

What is Qinlock and how is it marketed?

Qinlock is an oral kinase inhibitor approved by the FDA on May 15, 2020, for adults with advanced gastrointestinal stromal tumor (GIST) previously treated with three or more kinase inhibitors, including imatinib. The active ingredient is ripretinib, a switch-control tyrosine kinase inhibitor targeting KIT and PDGFRA signaling.[1]

Product attribute	Qinlock
Active ingredient	Ripretinib
Strength	50 mg per tablet
Dosage form	Immediate-release film-coated tablet
FDA approval	May 15, 2020
Approved indication	Advanced GIST after prior treatment with at least three kinase inhibitors
Standard dose	150 mg once daily
Dose escalation	150 mg twice daily after disease progression in certain patients
Administration	With or without food
Original sponsor	Deciphera Pharmaceuticals
Current parent	Ono Pharmaceutical
Therapeutic category	Oncology, kinase inhibitor
Primary market	United States, with international commercialization

The requirement for chronic daily administration and dose escalation creates recurring tablet demand. It also increases the value of consistent excipient quality, coating performance, tablet robustness, and supply continuity.

What excipients are used in Qinlock tablets?

The FDA prescribing information identifies conventional excipients in the Qinlock tablet core and film coating.[1] The formulation includes:

• Colloidal silicon dioxide
• Crospovidone
• Hypromellose
• Lactose monohydrate
• Magnesium stearate
• Microcrystalline cellulose
• Polysorbate 80
• Sodium lauryl sulfate
• Talc
• Titanium dioxide
• Yellow ferric oxide

The exact role of each excipient is commercially relevant.

Excipient	Likely formulation function	Commercial relevance
Lactose monohydrate	Diluent and tablet bulk	High-volume, multi-source commodity with grade-specific performance requirements
Microcrystalline cellulose	Compression aid and diluent	Important for tablet hardness, disintegration, and manufacturability
Crospovidone	Superdisintegrant	Supports immediate release and dissolution
Colloidal silicon dioxide	Glidant and flow aid	Controls powder flow and blend uniformity
Magnesium stearate	Lubricant	Requires controlled concentration and blending time
Sodium lauryl sulfate	Wetting agent and dissolution aid	Can affect dissolution, irritation profile, and process performance
Polysorbate 80	Wetting or dispersion aid	Requires control of oxidation, peroxide formation, and supplier quality
Hypromellose	Film-forming polymer	Supports coating integrity and appearance
Talc	Coating aid and anti-tacking agent	Used in film coating and requires controlled particle characteristics
Titanium dioxide	Opacifier and color modifier	Subject to regional regulatory restrictions and reformulation pressure
Yellow ferric oxide	Colorant	Supports product identification and may require country-specific color compliance

The formulation is not dependent on a proprietary excipient. That lowers the barrier to supply substitution but raises the importance of demonstrating equivalence in powder flow, compression, disintegration, dissolution, film appearance, stability, and impurity control.

What excipient strategy is appropriate for Qinlock?

The optimal strategy is a controlled, dual-source platform built around established compendial grades rather than a new excipient.

Supply-chain strategy

Qinlock manufacturers or contract manufacturers would normally prioritize:

1. Dual sourcing for lactose monohydrate, microcrystalline cellulose, crospovidone, hypromellose, and coating pigments.
2. Supplier qualification by grade, particle-size distribution, moisture, bulk density, microbial quality, and elemental impurities.
3. Change-control agreements that require advance notification of manufacturing-site, process, or specification changes.
4. Low-peroxide and oxidation-controlled grades for polysorbate 80.
5. Nitrosamine-risk assessments for excipients and processing materials.
6. Regional compliance for colorants, titanium dioxide, and animal-origin status.
7. Buffer inventory for oncology products with concentrated manufacturing footprints.

The commercial value of these activities is greater than the value of selling a generic grade alone. A supplier that can provide regulatory documentation, analytical bridging, global manufacturing redundancy, and technical support has a stronger position than a commodity producer.

Manufacturing strategy

The tablet formulation is compatible with conventional direct compression or wet-granulation development approaches, subject to the reference product's process and critical quality attributes. A generic manufacturer would need to control:

• Blend uniformity for a low-dose active ingredient relative to tablet mass
• Magnesium stearate lubrication time
• Tablet hardness and friability
• Disintegration and dissolution across multiple media
• Coating weight gain and color uniformity
• Stability under long-term and accelerated conditions
• Extractables and leachables from packaging
• Photostability and moisture protection

Because patients may receive three tablets daily at the standard dose, tablet dimensions, swallowability, packaging efficiency, and dose-count convenience have commercial significance.

What formulation opportunities exist beyond the Qinlock tablet?

The largest lifecycle opportunities involve patient convenience and manufacturing efficiency rather than a simple copy of the 50 mg tablet.

Higher-strength tablet

A 100 mg or 150 mg tablet could reduce pill burden for patients receiving 150 mg once daily or twice daily. The commercial benefit would be greatest for dose-escalated patients. A higher-strength tablet would require a new demonstration of blend uniformity, dissolution, dose proportionality, stability, and potentially bioequivalence.

A higher-strength product could support:

• Lower tablet count
• Smaller packaging volume
• Lower distribution cost
• Improved adherence
• Differentiation in markets where treatment duration is extended

It could also create a new formulation patent position if the product has a distinct composition, manufacturing process, or release profile. Freedom-to-operate analysis would be required against Deciphera/Ono patents and regulatory exclusivity.

Pediatric or dysphagia-friendly dosage forms

GIST is primarily an adult oncology indication, so pediatric demand is limited. A liquid, multiparticulate, orally disintegrating, or sprinkle formulation could still target patients with swallowing difficulty and broaden administration flexibility.

The main technical constraints would be:

• Ripretinib solubility and suspension uniformity
• Taste masking
• Chemical and physical stability
• Dose accuracy
• Container compatibility
• Potential light sensitivity
• In-use stability after opening
• Acceptability of surfactants and preservatives

A liquid formulation could qualify for a 505(b)(2) pathway if it relies partly on the reference product's safety and efficacy data while introducing a materially different dosage form.[2]

Excipient substitution

A substitute formulation could replace:

• Lactose with mannitol, dibasic calcium phosphate, or another diluent
• Crospovidone with croscarmellose sodium or sodium starch glycolate
• Titanium dioxide with an alternative opacifier or color system
• Polysorbate 80 with another wetting agent
• Conventional coating materials with a more regionally acceptable film system

Substitution would not automatically create a commercially defensible product. For an immediate-release tablet, the key question is whether the change preserves dissolution and bioequivalence while improving cost, supply security, tolerability, or geographic registration.

What patent protection affects Qinlock excipient opportunities?

The active-ingredient and formulation patent estate is more important than the excipient identity alone. Excipient suppliers generally do not infringe a drug patent merely by selling a standard compendial material. Risk increases when a supplier or drug developer markets a finished ripretinib product using a protected formulation, manufacturing process, dosage regimen, or method of treatment.

Composition-of-matter protection

Ripretinib's core patent protection extends beyond the seven-year orphan-drug exclusivity period. The relevant composition and related patent families have been publicly associated with protection into the 2030s, subject to patent-term adjustments, terminal disclaimers, patent-term extension, claim scope, and jurisdiction.[3][4]

The commercial implication is that a generic manufacturer cannot rely solely on the end of orphan exclusivity. It must evaluate:

• Paragraph IV certification risk
• Patent expiration dates
• Listed formulation and method-of-use patents
• Patent-term extension
• Patent litigation exposure
• Non-infringement and invalidity positions
• Potential launch-at-risk economics

Formulation and manufacturing claims

The use of common excipients does not eliminate formulation risk. Claims may cover:

• Specific ripretinib solid forms
• Particle-size characteristics
• Pharmaceutical compositions
• Tablet manufacturing processes
• Dissolution or release characteristics
• Combination use with other anticancer agents
• Treatment methods involving dose escalation

A substitute formulation using different excipients may reduce literal infringement risk but still require analysis of claim construction and equivalents. A process patent can also affect contract manufacturing even when the final tablet composition differs.

Orange Book status

Qinlock is an FDA-approved small-molecule drug listed in the Orange Book. The Orange Book, rather than commercial patent summaries, is the operative source for FDA-listed patents, regulatory exclusivity, and generic application implications.[3]

The principal regulatory milestones are:

Milestone	Date or status
FDA approval	May 15, 2020
Orphan-drug exclusivity	Generally runs through May 15, 2027
NCE exclusivity	Runs independently from approval and may overlap with orphan exclusivity
Patent protection	Publicly reported patent protection extends into the 2030s
Generic pathway	ANDA with Paragraph IV, Paragraph III, or Section viii strategy, depending on listed claims
Biosimilar pathway	Not applicable because ripretinib is a small molecule

When does Qinlock lose exclusivity?

Qinlock does not have a single exclusivity date. Regulatory exclusivity and patent protection operate separately.

FDA exclusivity

The seven-year orphan-drug exclusivity period generally protects the approved indication through May 15, 2027. FDA cannot approve another drug for the same orphan indication during that period unless an applicable statutory exception applies.[2]

NCE exclusivity is separate and shorter. It generally lasts five years from approval, with a possible fourth-year Paragraph IV filing opportunity. Because Qinlock also received orphan designation, orphan exclusivity is the more commercially relevant near-term regulatory barrier.[2]

Patent expiration

Patent expiry is expected to control generic entry after regulatory exclusivity ends. Patent terms can extend beyond 2027 and may create a later entry date depending on the patents listed and the claims a generic applicant challenges.

A generic applicant can pursue:

• Paragraph III certification, accepting delayed entry until patent expiry
• Paragraph IV certification, asserting invalidity, unenforceability, or non-infringement
• Section viii carve-outs for method-of-use claims
• A negotiated settlement with the patent owner
• An at-risk launch after litigation or settlement analysis

Which companies are challenging Qinlock?

Public commercial competition consists mainly of alternative treatments for advanced GIST rather than direct generic ripretinib competition. Relevant competitors include:

• Imatinib, generally used earlier in the treatment sequence
• Sunitinib
• Regorafenib
• Avapritinib for selected PDGFRA exon 18-mutant GIST
• Clinical-stage KIT, PDGFRA, and broad-spectrum kinase inhibitors
• Future generic versions of established GIST therapies

The direct generic challenge to Qinlock depends on ANDA filings and Paragraph IV litigation. FDA approval of a generic is not assured merely because orphan exclusivity expires. A company must also overcome listed patents, obtain acceptable bioequivalence results, and address any exclusivity remaining for protected indications.

No biosimilar pathway applies. Ripretinib is a chemically synthesized small molecule, so competitive entry would occur through the ANDA or 505(b)(2) pathways rather than under the Biologics Price Competition and Innovation Act.

How strong is the Qinlock patent estate?

The estate is commercially meaningful because it combines an approved small molecule, an orphan indication, composition protection, and potential secondary protection around formulations and use. Its strength depends on claim validity and the number of enforceable patents remaining at the time of a generic filing.

Strength factor	Assessment
Approved active ingredient	Strong commercial position
Orphan indication	Strong through 2027 for the protected indication
Core patent duration	Extends beyond orphan exclusivity
Excipient dependence	Low; common excipients reduce composition-based differentiation
Formulation design-around	Possible in principle, but requires bioequivalence and FTO work
Manufacturing barriers	Moderate; process validation and supply qualification remain important
Biosimilar barrier	Not relevant
Generic litigation risk	Material after Paragraph IV filings
Product differentiation	Possible through dose strength, administration, packaging, or dosage form

The estate is less defensible if a competitor can develop a bioequivalent tablet with a materially different excipient system and avoid enforceable formulation claims. It is more defensible if patent claims cover the active polymorph, broad pharmaceutical composition, or treatment method used in the commercial label.

What commercial opportunities exist for excipient companies?

The opportunity set is concentrated in qualified supply and lifecycle development.

Near-term opportunities

Excipient suppliers can compete for:

• Lactose monohydrate and microcrystalline cellulose supply
• Crospovidone and colloidal silicon dioxide
• Hypromellose film-coating systems
• Low-peroxide polysorbate 80
• Alternative titanium-dioxide-free coatings
• Global regulatory support
• Second-source qualification
• Contract formulation and analytical bridging

Higher-value opportunities

The strongest margins are likely in integrated services:

1. Excipient selection and compatibility testing.
2. Design-space development for tablet compression and coating.
3. Generic formulation development for an ANDA.
4. 505(b)(2) dosage-form development.
5. Stability and dissolution method development.
6. Regulatory change packages for supplier or grade changes.
7. Oncology-focused packaging and supply-chain qualification.

A supplier with a proprietary co-processed excipient could gain differentiation if it improves flow, compression, tablet robustness, or dissolution without creating a new regulatory burden. The product must still demonstrate equivalence against the reference formulation.

What revenue exposure exists for Qinlock?

Qinlock is an important product for Ono because it is a targeted therapy with long-duration use in a small, high-value oncology population. Deciphera reported Qinlock net product revenues of approximately $215 million in 2023 before its acquisition by Ono.[5]

Revenue exposure is linked to:

• The number of patients receiving fourth-line or later GIST treatment
• Duration of therapy
• Dose escalation after progression
• Competition from later-generation KIT or PDGFRA inhibitors
• Generic entry timing
• Payer restrictions
• International reimbursement
• Continued clinical use after progression

A lower-cost generic could create significant payer pressure after patent expiry, but a higher-strength tablet or differentiated dosage form could preserve branded value in selected patient segments.

What generic launch scenarios exist for Qinlock?

Scenario 1: Delayed generic entry

A generic applicant accepts listed patents and enters after the latest enforceable patent expires. This minimizes litigation cost but delays market access.

Scenario 2: Paragraph IV challenge

The applicant challenges core or secondary patents. The patent owner may initiate litigation, triggering the statutory 30-month stay under applicable conditions.[2] Commercial entry then depends on settlement, court outcome, appeal, or at-risk launch.

Scenario 3: Section viii carve-out

If listed patents cover only a method of use, an applicant may attempt to omit the protected indication from its label. This strategy is more difficult if the remaining label would still induce use covered by the patent claims.

Scenario 4: 505(b)(2) reformulation

A company could pursue a higher-strength tablet, liquid, orally disintegrating tablet, or other dosage form. This may provide differentiation but can face additional clinical, formulation, and patent hurdles.

Key Takeaways

• Qinlock is a 50 mg immediate-release ripretinib tablet using standard pharmaceutical excipients.
• The direct excipient opportunity is strongest in qualified supply, dual sourcing, coating systems, and regulatory support.
• A new excipient alone is unlikely to create substantial commercial differentiation.
• Higher-strength tablets and dysphagia-friendly dosage forms are the clearest lifecycle opportunities.
• Orphan exclusivity generally runs through May 15, 2027, but patent protection extends beyond that period.
• Generic competition will likely depend on Orange Book patents, Paragraph IV challenges, litigation, and settlement terms.
• Biosimilar competition does not apply because Qinlock is a small-molecule drug.
• Excipient substitution can support an ANDA or 505(b)(2) strategy but must preserve bioequivalence, dissolution, stability, and manufacturing performance.
• Ono's acquisition of Deciphera gives Qinlock a larger corporate platform for global commercialization and lifecycle management.

FAQs About Qinlock Excipients, Patents, and Commercial Entry

Can lactose-free Qinlock be developed?

A lactose-free ripretinib tablet could be developed with mannitol, dibasic calcium phosphate, or another diluent. The product would require formulation optimization, comparative dissolution, stability testing, and an applicable FDA filing strategy.

Can Qinlock be supplied as a liquid?

A ripretinib oral liquid or suspension could target patients unable to swallow tablets. The main development issues would be solubility, dose uniformity, taste, chemical stability, and in-use stability.

Is titanium dioxide in Qinlock commercially replaceable?

The coating system can potentially be reformulated with an alternative opacifier or color system. The replacement would require assessment of appearance, light protection, stability, processability, and country-specific regulatory requirements.

Does an excipient supplier need a license from Ono to sell ingredients for Qinlock?

A supplier of standard excipients generally does not need a product patent license merely to sell the excipient. A license may become relevant if the supplier participates in a finished product, proprietary formulation, patented process, or other activity covered by enforceable claims.

What is the most attractive generic strategy for ripretinib?

The most attractive strategy is likely a bioequivalent immediate-release tablet with a robust supply chain and a carefully assessed Paragraph III or Paragraph IV position. A 505(b)(2) product could offer differentiation but would carry higher formulation and regulatory complexity.

References

1. U.S. Food and Drug Administration. (2023). Qinlock (ripretinib) prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2024). Qinlock: Drugs@FDA regulatory information.
4. United States Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System records for ripretinib and Qinlock-related patent families.
5. Deciphera Pharmaceuticals, Inc. (2024). Annual report on Form 10-K for the fiscal year ended December 31, 2023.